Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness

NCT06487832 · Recruiting

Last updated 2026-05-28

This clinical trial tests whether a GLP1 receptor agonist nasal spray affects brain insulin responsiveness in people who are normal weight, overweight, or have obesity.

Status Recruiting Currently enrolling participants.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, single-blind basic-science study

Participants 60 people Planned (estimated).

Who can join Ages 18–70 · all sexes Healthy volunteers accepted.

Timeline Started 2024-07 · est. completion 2027-12

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT06487832 ↗

Description as written by the study sponsor.

The overarching goal of the current study is to investigate the effect of GLP-1 on brain insulin responsiveness in a randomized, single-blinded, within subject cross-over study design. To this end, investigators will compare the effect of the administration of semaglutide versus placebo, followed by an fMRI with administration of intranasal insulin or placebo.

Treatments tested

Subcutaneous GLP1-RA Other

Subcutaneous administration of semaglutide
Subcutaneous placebo Other

Subcutaneous administration of NaCl

Main thing measured	Cerebral response after insulin compared to placebo nasal spray
Sponsor	University Hospital Tuebingen
Conditions studied	Normal Weight, Overweight and Obesity, Insulin Sensitivity, Insulin Resistance
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06487832 ↗